---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-000796"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:15:02.447617+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech announces $15M private placement led by Velan Capital; appoints David Liu to board

## Summary
- Gross proceeds of $15M from sale of Series B-1 convertible preferred shares ($10K each) and 3.47M common shares at $1.92/share.
- Proceeds to fund Phase 2 study of EB06 (CXCL10 antibody) for nonsegmental vitiligo and for working capital.
- Velan Capital led placement; officers/directors purchased ~$1.1M of securities.
- David Liu, Senior Analyst at Velan Capital, appointed to Board of Directors effective immediately.
- Company to file resale registration statement within 30 days; beneficial ownership cap of 4.99% (or 9.99% opt-in).

## SEC filing metadata
- accession: 0001171843-25-000796
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 3.03, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184325000796/0001171843-25-000796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184325000796/f8k_021225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-000796
- JSON: https://secwatch.observer/filing/0001171843-25-000796.json
- Plain text: https://secwatch.observer/filing/0001171843-25-000796.txt

## Key facts
- Executive change
  David Liu was appointed as Director at Edesa Biotech, Inc..
  - Action: appointed
  - Role: Director
  source text: the Company appointed David Liu, the Lead Investor Nominee, to serve on the Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000117184325000796/0001171843-25-000796-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.